Zoladex® (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy

Miller, Robert M.; Frank, R. A.

doi:10.1111/j.1471-0528.1992.tb13539.x

Cited by 24 publications

(5 citation statements)

References 8 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of Zoladex led to hypoestrogenic pharmacological side effects. The incidence of these elicited events was similar to those reported pre viously [8] but were not sufficiently severe to lead to with drawal except in a very small number of cases.…”

Section: Discussionsupporting

confidence: 68%

The Place of Zoladex® in Deferred Surgery for Uterine Fibroids

et al. 1996

View full text Add to dashboard Cite

Two hundred and forty-seven patients with uterine fibroids were randomized to surgery alone or 3 months’ Zoladex® (Zeneca, Macclesfield, Ches., UK) followed by surgery. Zoladex significantly reduced uterine and fibroid volumes (p = 0.0001). There was a significantly (p = 0.002) greater mean rise in haemoglobin from entry to preoperation in the Zoladex group (1 g/dl) compared with the surgery-alone group (0.3 g/dl) as well as a tendency towards easier surgery, and reduced operative blood loss. Zoladex-treated patients had a significantly (p = 0.016) shorter hospital stay and pelvic pain and abdominal pressure symptoms were significantly (p < 0.0001) reduced in this group. Zoladex was well tolerated.

show abstract

Section: Discussionsupporting

confidence: 68%

The Place of Zoladex® in Deferred Surgery for Uterine Fibroids

et al. 1996

View full text Add to dashboard Cite

show abstract

“…There was a trend of increasing incidence of ovarian failure in the < 30 year group, [30][31][32][33][34][35][36][37][38][39] year group, and those > 40 years, respectively. This finding is in agreement with those of a study using oral cyclophosphamide that also demonstrated a continuous age related trend.…”

Section: Discussionmentioning

confidence: 99%

Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.

McDermott¹,

Powell²

1996

Annals of the Rheumatic Diseases

133

View full text Add to dashboard Cite

Objective-To investigate the incidence of ovarian failure after pulse cyclophosphamide treatment in systemic lupus erythematosus (SLE) and to compare this with two control groups: SLE patients treated with azathioprine, and a healthy age matched population. Methods-All women patients with SLE treated with pulse cyclophosphamide in our departnent were identified and questioned concerning menstrual history. All the hospital notes were reviewed and details recorded on dose of cyclophosphamide, duration of treatment, side effects and lowest pretreatment neutrophil and leucocyte counts during the course of treatment. Disease controls were recruited from our departnent and healthy controls from the local family health services authority (FHSA) register. Results-Incidence of ovarian failure in the premenopausal cyclophosphamide treated group was 54% and the incidence of premature menopause (occurring before age 40 years) was 41%. Increasing age at start of treatment showed a linear trend with incidence ofovarian failure (p = 0.01). Using logistic regression, increasing duration oftreatment was related to incidence of ovarian failure (p = 0 047 in those treated age 35 years or younger). An association between the lowest neutrophil count throughout the treatment period, when taken immediately before each planned cyclophosphamide pulse, and the incidence of ovarian failure was also demonstrated (p = 0 04 in those treated before age 40 years). Conclusion-Ovarian failure-in particular, premature failure after treatment with pulse cyclophosphamide-is common.

show abstract

“…Several studies have demonstrated the efficacy of goserelin in normalising haematological values in anaemic women with fibroids and excessive uterine bleeding 19 . Candiani et al 13 administered goserelin subcutaneously every 28 days for 24 weeks to 16 patients aged 24–53 years (mean 46 years) with severe sideropenic anaemia (haemoglobin < 9 g/dl) and leiomyoma‐associated menorrhagia of 6–16 months' duration.…”

Section: Goserelin and The Anaemic Patientmentioning

confidence: 99%